Research Study

A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus
Principal Investigator 
Eric M. Yoshida

Overview

Body Locations and Systems 
Hepatitis B
ClinicalTrials.gov# 
NCT02751996
Status 
Recruiting
Study Start/End 
May 31, 2016 to Mar 31, 2019
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Jo-Ann Ford, Research Coordinator
Phone 
604-875-5705
Email Address 
jo-ann.ford@vch.ca
Purpose of Study 

This is a Phase 2, open-label,randomized, multiple dose, varied administration regimen study with 2 parts (Parts A and B) in Subjects Infected with Chronic Hepatitis B Virus

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.